CompletedNot Applicable

A Registry of Patients With Moderate to Severe Plaque Psoriasis

Canada2,376 participantsStarted 2015-12-23

Plain-language summary

The main purpose of the current study will be to provide real - world evidence regarding the safety and effectiveness of secukinumab in the management of patients with moderate to severe chronic plaque psoriasis.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. \- Patients able to give written informed consent
✓. \- Patients at least 18 years of age at time of informed consent signature
✓. \- Confirmed diagnosis of chronic moderate to severe chronic plaque-type psoriasis diagnosed by a specialist and presence of moderate to severe psoriasis symptoms according to physician's clinical judgment at the time of recruitment.
✓. \- Patients initiating a treatment for psoriasis as per regional policy. This will include secukinumab, other biologics, systemic treatments, and phototherapy. Decision to treat with any of the above-mentioned treatments must have been reached prior to and independently of recruitment in the study.
✓. \- Treatments prescribed in accordance to the product monograph and regional regulatory and reimbursement policies
✓. \- Patients able to understand and communicate with the investigator and comply with the requirements of the study.

Exclusion criteria

✕. \- Unwillingness or inability to comply with the study requirements
✕. \- Participation in a clinical trial of an investigational drug, concurrently or within the last 30 days.

What they're measuring

Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

Timeframe: Change from Baseline through month 60

Trial details

NCT IDNCT02786186

SponsorNovartis Pharmaceuticals

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2026-01-22

View on ClinicalTrials.gov More Psoriasis trials